Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. SoftBank Group Corp.
  6. News
  7. Summary
    9984   JP3436100006

SOFTBANK GROUP CORP.

(9984)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chinese mRNA vaccine developer Abogen raises $300 mln from SoftBank Vision Fund, others

11/29/2021 | 06:12am EST

BEIJING, Nov 29 (Reuters) - Chinese mRNA technology firm Suzhou Abogen Biosciences said on Monday it had raised $300 million from investors including SoftBank Group Corp's Vision Fund to support the development of its potential COVID-19 shot and other drug candidates.

The capital raise, led by SoftBank Vision Fund and 5Y Capital, also attracted investors such as Chimera Abu Dhabi, Fortune Ocean and Mirae Asset Financial Group.

It came after Abogen received $720 million in August from investors including Temasek Holdings and Hillhouse-backed GL Ventures.

The proceeds will also be used to improve its mRNA platform with technologies such as artificial intelligence, Abogen said in a statement.

Reuters reported on Friday, citing sources, that SoftBank was in the final stage of investment talks with Abogen and was interested in leading the capital raise. (Reporting by Roxanne Liu and Ryan Woo; Editing by Kirsten Donovan)


© Reuters 2021
All news about SOFTBANK GROUP CORP.
01/21Chime lines up Goldman Sachs for blockbuster IPO -sources
RE
01/21Japan Index Records Third Consecutive Week of Losses; Toyota Suspends Local Factories
MT
01/20Softbank Group to Raise $4.8 Billion from Yen Bond Issuance
MT
01/20ByteDance's Revenue Surges 70% in 2021 to $58 Billion
MT
01/20SOFTBANK : Decides on Terms and Conditions for Issuance of its Sustainability Bond (&ldquo..
PU
01/20AI software firm 6sense valued at $5.2 bln after SoftBank joins funding round
RE
01/20Nikkei rebounds from 5-month low on China rate cut, game-maker rally boost
RE
01/19ByteDance Dissolves Investment Arm Amid Restructuring
MT
01/19Nikkei rebounds from five-month low as Sony, Toyota advance
RE
01/18SoFi shares bounce after winning bank approval
RE
More news
Analyst Recommendations on SOFTBANK GROUP CORP.
More recommendations
Financials
Sales 2022 6 119 B 53 802 M 53 802 M
Net income 2022 1 058 B 9 304 M 9 304 M
Net Debt 2022 15 202 B 134 B 134 B
P/E ratio 2022 8,73x
Yield 2022 0,80%
Capitalization 9 380 B 82 440 M 82 482 M
EV / Sales 2022 4,02x
EV / Sales 2023 4,00x
Nbr of Employees 58 786
Free-Float -
Chart SOFTBANK GROUP CORP.
Duration : Period :
SoftBank Group Corp. Technical Analysis Chart | 9984 | JP3436100006 | MarketScreener
Technical analysis trends SOFTBANK GROUP CORP.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 5 487,00 JPY
Average target price 9 718,00 JPY
Spread / Average Target 77,1%
EPS Revisions
Managers and Directors
Masayoshi Son Chairman & Executive President
Yoshimitsu Goto CFO, Director & Senior Managing Executive Officer
Raul Marcelo Claure Chief Operating Officer & Executive Vice President
Tim Mackey Chief Legal Officer & Group Compliance Officer
Masami Iijima Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
SOFTBANK GROUP CORP.0.98%82 440
AT&T INC.9.84%192 950
T-MOBILE US-12.38%129 977
KDDI CORPORATION6.54%70 050
AMÉRICA MÓVIL, S.A.B. DE C.V.-8.85%62 682
VODAFONE GROUP PLC4.70%44 358